B-Cell Targeting Has Benefit in Severe Lupus (CME/CE)

(MedPage Today) -- Although an inhibitor of B-cell activating factor failed to meet the primary endpoint in a phase II trial for lupus, beneficial effects were seen in patients with severe disease at baseline, researchers reported.

Source: MedPage Today Primary Care - April 24, 2014 Category: Primary Care Source Type: news